CoChat

Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis

Open access

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Several recent trials indicate low-dose ketamine produces rapid antidepressant effects. However, uncertainty remains in several areas: dose response, consistency across patient groups, effects on suicidality, and possible biases arising from crossover trials. METHODS: A systematic search was conducted for relevant randomized trials in Medline, Embase, and PsycINFO databases up to August 2014. The primary endpoints were change in depression scale scores at days 1, 3 and 7, remission, response, suicidality, safety, and tolerability. Data were independently abstracted by 2 reviewers. Where possible, unpublished data were obtained on treatment effects in the first period of crossover trials. RESULTS: Nine trials were identified, including 201 patients (52% female, mean age 46 years). Six trials assessed low-dose ketamine (0.5 mg/kg i.v.) and 3 tested very low-dose ketamine (one trial assessed 50 mg intra-nasal spray, another assessed 0.1-0.4 mg/kg i.v., and another assessed 0.1-0.5 mg/kg i.v., intramuscular, or s.c.). At day 3, the reduction in depression severity score was less marked in the very low-dose trials (P homogeneity <.05) and among bipolar patients. In analyses excluding the second period of crossover trials, response rates at day 7 were increased with ketamine (relative risk 3.4, 95% CI 1.6-7.1, P=.001), as were remission rates (relative risk 2.6, CI 1.2-5.7, P=.02). The absolute benefits were large, with day 7 remission rates of 24% vs 6% (P=.02). Seven trials provided unpublished data on suicidality item scores, which were reduced on days 1 and 3 (both P<.01) but not day 7. CONCLUSION: Low-dose ketamine appears more effective than very low dose. There is substantial heterogeneity in clinical response, with remission among one-fifth of patients at 1 week but most others having benefits that are less durable. Larger, longer term parallel group trials are needed to determine if efficacy can be extended and to further assess safety.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyv124

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Flow diagram for systematic review.
Figure 1. Flow diagram for systematic review.CC BY · PubMed Central
Figure 2. Potential sources of bias in included trials. See Methods for explanation of potential biases.
Figure 2. Potential sources of bias in included trials. See Methods for explanation of potential biases.CC BY · PubMed Central
Figure 3. Reductions in depression severity scores following single-dose ketamine in patients with major depression. (A) Placebo-corrected changes in Hamilton Depression Rating Sclae Scores (HAM-D). (B) Placebo-corrected changes in Montgomery-Åsberg Depression Rating Scale (MADRS). (C) Placebo-corrected percentage changes in HAM-D/MADRS. Data are placebo-corrected, and axes redrawn on a linear scale to avoid a visual misrepresentation of how the treatment effect evolves over time. Lines with circular markers represent trials among patients with bipolar disorder depression. Other trials were among patients with unipolar depression. Lines with square markers represent patients remained on pretrial antidepressant treatment. Solid lines represent low dose (i.v. ketamine 0.5mg/kg). Dashed lines represent very low dose (intranasal ketamine 50mg or i.v. 0.3mg/kg; Lai et al. and Loo et al. used an ascending dose design and the data for 0.3mg/kg are shown).
Figure 3. Reductions in depression severity scores following single-dose ketamine in patients with major depression. (A) Placebo-corrected changes in Hamilton Depression Rating Sclae Scores (HAM-D). (B) Placebo-corrected changes in Montgomery-Åsberg Depression Rating Scale (MADRS). (C) Placebo-corrected percentage changes in HAM-D/MADRS. Data are placebo-corrected, and axes redrawn on a linear scale to avoid a visual misrepresentation of how the treatment effect evolves over time. Lines with circular markers represent trials among patients with bipolar disorder depression. Other trials were among patients with unipolar depression. Lines with square markers represent patients remained on pretrial antidepressant treatment. Solid lines represent low dose (i.v. ketamine 0.5mg/kg). Dashed lines represent very low dose (intranasal ketamine 50mg or i.v. 0.3mg/kg; Lai et al. and Loo et al. used an ascending dose design and the data for 0.3mg/kg are shown).CC BY · PubMed Central
Figure 4. Difference in standardized mean mood score on days 1, 3, and 7 for crossover trials, first period only. Data are shown only for the first period in crossover trials. Hamilton Depression Rating Sclae Scores (HAM-D) was reported by Zarate et al., 2006 with the remainder reporting Montgomery-Åsberg Depression Rating Scale (MADRS). 95% CIs of treatment effects are represented by horizontal lines for individual trials, by grey diamonds for trial subgroups, and by black diamonds for all trials. A vertical dashed line goes through the overall pooled result for all trials, with a result to the left of the vertical line indicating a reduction in mood score in the ketamine group.
Figure 4. Difference in standardized mean mood score on days 1, 3, and 7 for crossover trials, first period only. Data are shown only for the first period in crossover trials. Hamilton Depression Rating Sclae Scores (HAM-D) was reported by Zarate et al., 2006 with the remainder reporting Montgomery-Åsberg Depression Rating Scale (MADRS). 95% CIs of treatment effects are represented by horizontal lines for individual trials, by grey diamonds for trial subgroups, and by black diamonds for all trials. A vertical dashed line goes through the overall pooled result for all trials, with a result to the left of the vertical line indicating a reduction in mood score in the ketamine group.CC BY · PubMed Central
Figure 5. Effects of single-dose ketamine on response and remission rates at days 1, 3, and 7. Data included from the parallel trial (Murrough et al.) and from the first period of crossover trials. 95% CIs of treatment effects are represented by horizontal lines for individual trials and by diamonds for subgroups or all trials. Results on the right side of the vertical line indicated benifit in the ketamine group.
Figure 5. Effects of single-dose ketamine on response and remission rates at days 1, 3, and 7. Data included from the parallel trial (Murrough et al.) and from the first period of crossover trials. 95% CIs of treatment effects are represented by horizontal lines for individual trials and by diamonds for subgroups or all trials. Results on the right side of the vertical line indicated benifit in the ketamine group.CC BY · PubMed Central
Figure 6. Standardized mean differences in suicide item scores at days 1, 3, and 7. Suicide item score from Hamilton Depression Rating Sclae Scores (HAM-D) provided by Zarate et al., 2006, and from Montgomery-Åsberg Depression Rating Scale (MADRS) for other trials. 95% CIls of treatment effects are represented by horizontal lines for individual trials and by diamonds for all trials. A vertical dashed line goes through the overall pooled result for all trials, with a result to the left of the vertical line indicating a reduction in mood suicide item score in the ketamine group.
Figure 6. Standardized mean differences in suicide item scores at days 1, 3, and 7. Suicide item score from Hamilton Depression Rating Sclae Scores (HAM-D) provided by Zarate et al., 2006, and from Montgomery-Åsberg Depression Rating Scale (MADRS) for other trials. 95% CIls of treatment effects are represented by horizontal lines for individual trials and by diamonds for all trials. A vertical dashed line goes through the overall pooled result for all trials, with a result to the left of the vertical line indicating a reduction in mood suicide item score in the ketamine group.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 2

  1. Aitken, 1969, Measurement of feelings using visual analogue scales, Proc R Soc Med, 62, 989
  2. RevMan (2014) The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Cited by

See all 226

Metadata

Authors
Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., Mitchell, P. B., & Rodgers, A.
Affiliations
The University of Sydney (AU)
Corresponding author
Loo, Colleen
Venue
International Journal of Neuropsychopharmacology
Published
2015-11-17
Volume
19
Issue
4
Pages
pyv124
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2197394318
Cited by
226
References
44
Citations by year
2026: 8 · 2025: 12 · 2024: 22 · 2023: 22 · 2022: 22 · 2021: 20 · 2020: 29 · 2019: 26 · 2018: 28 · 2017: 24 · 2016: 13
FWCI
2.72
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
  • UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
  • Figshare (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
  • NOVA (University of Newcastle Australia) (submittedVersion)
Funders
National Institute of Mental Health (K23MH104465)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
ketamine, major depressive disorder, low-dose ketamine, rapid antidepressant effects, dose-response relationship, remission, response rate, suicidality, bipolar disorder, crossover trial, safety and tolerability
MeSH terms
Antidepressive Agents, Major Depressive Disorder, Humans, Ketamine, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.